MX2015016114A - Biomarcadores de expresion de gen y sus usos para aplicacion de diagnosis y prognosis en pacientes potencialmente en necesidad de tratamiento de inhibidor de histona desacetilasa (hdac). - Google Patents

Biomarcadores de expresion de gen y sus usos para aplicacion de diagnosis y prognosis en pacientes potencialmente en necesidad de tratamiento de inhibidor de histona desacetilasa (hdac).

Info

Publication number
MX2015016114A
MX2015016114A MX2015016114A MX2015016114A MX2015016114A MX 2015016114 A MX2015016114 A MX 2015016114A MX 2015016114 A MX2015016114 A MX 2015016114A MX 2015016114 A MX2015016114 A MX 2015016114A MX 2015016114 A MX2015016114 A MX 2015016114A
Authority
MX
Mexico
Prior art keywords
hdac inhibitor
diagnostic
need
inhibitor treatment
gene expression
Prior art date
Application number
MX2015016114A
Other languages
English (en)
Inventor
Thomas Herz
Astrid Zimmermann
Volker Gekeler
Eike Staub
Thomas Maier
Hella Kohlhof
Robert Doblhofer
Thomas Beckers
Marina Mollenhauer-Thein
Markus Böhm
Hans-Peter Hofmann
Timo Wittenberger
Martin Elmlinger
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of MX2015016114A publication Critical patent/MX2015016114A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/682—Signal amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la utilización de uno o más genes que se seleccionan a partir del grupo que comprende ZFP64, DPP3, CCDC43, HIST2H4A/B, KDELC2 y MICALL1 como biomarcadores para tratamiento de inhibidor de HDAC. La expresión y/o cambio de los genes antes mencionados de preferencia se determina a través del ARNm correspondiente respectivo o de una o más proteínas expresadas por los genes antes mencionados.
MX2015016114A 2013-05-24 2014-05-22 Biomarcadores de expresion de gen y sus usos para aplicacion de diagnosis y prognosis en pacientes potencialmente en necesidad de tratamiento de inhibidor de histona desacetilasa (hdac). MX2015016114A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361827201P 2013-05-24 2013-05-24
US201361865712P 2013-08-14 2013-08-14
US201461935914P 2014-02-05 2014-02-05
PCT/EP2014/060532 WO2014187894A1 (en) 2013-05-24 2014-05-22 Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment

Publications (1)

Publication Number Publication Date
MX2015016114A true MX2015016114A (es) 2016-07-21

Family

ID=50771295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016114A MX2015016114A (es) 2013-05-24 2014-05-22 Biomarcadores de expresion de gen y sus usos para aplicacion de diagnosis y prognosis en pacientes potencialmente en necesidad de tratamiento de inhibidor de histona desacetilasa (hdac).

Country Status (12)

Country Link
US (1) US20160215348A1 (es)
EP (1) EP3004377A1 (es)
JP (1) JP2016521543A (es)
KR (1) KR20160010498A (es)
CN (1) CN105408498A (es)
AU (1) AU2014270380A1 (es)
BR (1) BR112015028997A2 (es)
CA (1) CA2912973A1 (es)
EA (1) EA201501137A1 (es)
HK (1) HK1223129A1 (es)
MX (1) MX2015016114A (es)
WO (1) WO2014187894A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034234A1 (ko) * 2015-08-21 2017-03-02 서울대학교 산학협력단 Hdac 억제제 내성을 갖는 암 치료용 복합제제
CN110412268A (zh) * 2018-04-27 2019-11-05 刘晓健 诊断经典霍奇金淋巴瘤的结外累犯的标志物及其应用
CN112691199A (zh) * 2021-01-26 2021-04-23 冠科生物技术(苏州)有限公司 一种预测病患对抑制剂反应的标志物及其使用方法
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859502B2 (en) * 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CN104056270B (zh) * 2013-02-21 2018-11-09 中国人民解放军军事医学科学院野战输血研究所 用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂

Also Published As

Publication number Publication date
CN105408498A (zh) 2016-03-16
KR20160010498A (ko) 2016-01-27
JP2016521543A (ja) 2016-07-25
HK1223129A1 (zh) 2017-07-21
CA2912973A1 (en) 2014-11-27
BR112015028997A2 (pt) 2017-10-24
US20160215348A1 (en) 2016-07-28
EA201501137A1 (ru) 2016-06-30
AU2014270380A1 (en) 2015-11-19
WO2014187894A1 (en) 2014-11-27
EP3004377A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
PH12016501763A1 (en) Multispecific antibodies
JO3792B1 (ar) تركيبات الجسم المضاد لـ flt3 و cd3
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA202090946A2 (ru) Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
MX2017013348A (es) Construcciones de anticuerpos biespecificos contra cdh3 y cd3.
EA201400178A1 (ru) Лечение рака молочной железы
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
PH12016500580A1 (en) Conjugated antibodies against ly75 for the treatment of cancer
NZ738100A (en) Igfbp3 and uses thereof
MX2016005956A (es) Anticuerpos especificos para fcrn.
MX369662B (es) Granulos de harina de microalgas y proceso de preparacion de estos.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
MX2015016114A (es) Biomarcadores de expresion de gen y sus usos para aplicacion de diagnosis y prognosis en pacientes potencialmente en necesidad de tratamiento de inhibidor de histona desacetilasa (hdac).
MX2017011198A (es) Biomarcadores para preeclampsia.
MX368486B (es) Plantas cucurbitaceas androceas, metodos de obtencion y usos de dichas plantas cucurbitaceas.
MX364626B (es) Péptidos miméticos.
IN2014DN08312A (es)
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201071163A1 (ru) Применение дефенсинов против менингита
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза